[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642326":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":58,"collaborators":28,"id":60,"slug":28,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":28,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":28,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":28,"overallStatus":78,"whyStopped":28,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Shanghai Jeyou Pharmaceutical Co., Ltd.","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL","JMKX000197",[13],"Drug: JMKX000197",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm B",[13],{"label":18,"type":19,"description":20,"interventionNames":21},"Arm C","ACTIVE_COMPARATOR","Cisplatin",[22],"Drug: Cisplatin",[24,29],{"type":25,"name":11,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Intrapleural administration",[9,15],null,{"type":25,"name":20,"description":26,"armGroupLabels":30,"otherNames":28},[18],[32],{"name":33,"affiliation":34,"role":35},"Jie Wang","Cancer Institute and Hospital, Chinese Academy of Medical Sciences","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":28,"email":41},"Yujia Song","CONTACT","+8615640506016","songyujia@jeyoupharma.com",[43],{"facility":44,"status":28,"city":45,"state":28,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Cancer Hospital, Chinese Academy of Medical Sciences","Beijing","100017","China",{"type":49,"coordinates":50},"Point",[51,52],116.39723,39.9075,{"lat":52,"lon":51},[55],{"name":33,"role":39,"phone":56,"phoneExt":28,"email":57},"+8613910704669","zlhuxi@163.com",{"type":59,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100642326",false,"NCT07649369","A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion","A Randomized, Controlled, Double-Blind, Multi-center Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion","Inclusion Criteria:\n\n* Participants with advanced solid tumors diagnosed by histopathology or cytopathology.\n* Moderate to large pleural effusions require intervention.\n* ECOG performance status: 0 to 2.\n* Life expectancy ≥ 3 months\n* Adequate organ function.\n* The serum pregnancy test of female participants of childbearing potential should be negative within 7 days prior to enrollment and must not be breastfeeding. With a fertile female\u002Fmale must agree to use medically accepted non-pharmacological contraception during the study and for 6 months after the last dose.\n\nExclusion Criteria:\n\n* Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.\n* Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.\n* Known allergies to the study drug or its excipient components.\n* Have participated in other clinical trials within 28 days prior to randomization.\n* Major surgery within 28 days prior to randomization.\n* Central nervous system metastatic disease, leptomeningeal disease, or cord compression.\n* Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases.\n* Active infections that require systemic treatment.\n* Have a history of organ transplantation.\n* Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.","ALL","18 Years","75 Years",{"count":70,"type":71},120,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","This study aims to evaluate the efficacy and safety of intrapleural JMKX000197 compared with intrapleural cisplatin in patients with malignant pleural effusion.",[77],"Malignant Pleural Effusions (Mpe)","NOT_YET_RECRUITING","2026-06-14",{"date":81,"type":82},"2026-06-16","ACTUAL",{"date":84,"type":71},"2026-08-17",{"date":86,"type":71},"2028-08-14",{"name":5,"class":6},1]